Autonomic regulation in muscular dystrophy

Corrado Angelini*, Rita Di Leo and Paola Cudia

Fondazione IRCCS San Camillo Hospital, Venice, Italy

*Correspondence: corrado.angelini@unipd.it

Keywords: myotonic dystrophy, autonomic nervous system, heart rate, dystrophin, congenital disorders of glycosylation

Autonomic Nervous System (ANS) function has been assessed in several muscular dystrophies. In the last two decades it has been recognized a significant relationship between ANS and cardiac mortality (Palladino et al., 2008). Cardiovascular ANS is frequently studied by using cardiovascular autonomic reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993). Heart rate variability (HRV) analysis, which involves measurement and analysis of heart rate variation, provides a quantitative marker of autonomic activity and has proved to be able to detect and measure modification in sympathetic or vagal activity. Moreover, it can be used to estimate the susceptibility for heart arrhythmias (Heart rate variability, 1996a,b).

DYSTROPHINOPATHIES

Duchenne (DMD) and Becker (BMD) muscular dystrophies are X-linked recessive disorders due to complete or partial loss of dystrophin protein. The presence of persistent sinus tachycardia, atrial and ventricular arrhythmias, sweating and chills has suggested an ANS involvement in these disorders.

Yotsukura et al. first described an impairment of ANS in 55 DMD, characterized by an increase in sympathetic activity and a reduction in parasympathetic output. These abnormalities were present early in the course of the disease, when cardiopulmonary function was still essentially normal, and became more marked with the progression of the disorder. The authors demonstrated also that, although HRV tended to decrease with the progress of clinical severity, it cannot be considered a good predictor of death in DMD (Yotsukura et al., 1995, 1998).

ANS impairment was confirmed by Lanza et al. (2001) and by Inoue et al. (2009) who proposed that the mean heart rate during night could be used as a simple measurement for evaluation of autonomic function and that early treatment against tachycardia should be initiated when a patient’s mean heart rate at night is > 71 beats/min.

The neuropathological evidence of ANS involvement in DMD has been shown in mdx mice, where a selective loss of the sympathetic superior cervical ganglion (SCG) neurons, combined with the dystrophin-associated muscle damage, might lead to ganglion neuron death (De Stefano et al., 2005).

In 1997, the arrhythmic profile in a population of 20 BMD patients was investigated to correlate the severity of arrhythmic events, the cardiac autonomic balance (assessed by HRV analysis in the time domain) and the degree of left systolic impairment (Ducceschi et al., 1997). In this study they observed a cardiac autonomic imbalance characterized by sympathetic predominance and an increased susceptibility to ventricular arrhythmias, even in the absence of overt cardiomyopathy; however, the severity of arrhythmic profile was closely related to the degree of left ventricular systolic dysfunction (Ducceschi et al., 1997).

In a subsequent study, 20 BMD patients were investigated with a battery of six cardiovascular autonomic tests and power spectral analysis of HRV (Vita et al., 2001). Although 11 patients revealed abnormal findings at some cardiovascular tests, none of them had a definite autonomic damage, as indicated by two or more abnormal tests. This clinical observation suggested therefore that autonomic involvement does not represent a major finding in BMD (Vita et al., 2001).

In 2006 the prognostic value of HRV for sudden death was evaluated in a population of 30 BMD patients and dilated cardiomyopathy compared with a control group of 30 normal subjects (Ammendola et al., 2006). An increment of sympathetic tone in BMD was observed, characterized by a lower HRV in the frequency and time domains and a higher mean heart rate than in the control group. HRV was lower in the high arrhythmic risk BMD group than in the remaining patients. All BMD patients who died had lower HRV than the minimum HRV recorded in the survivors and none of them had an abnormal standard deviation of all normal RR interval over 24 h (SDNN). SDNN is considered the most important parameter to estimate the adrenergic activity, being inversely related to it. This study concluded that ANS may have an important role in BMD and that SDNN values <100 ms may be a significant predictors of cardiac death, independent of clinical variables (Ammendola et al., 2006). No study has been so far conducted in DMD/BMD carriers.

MYOTONIC DYSTROPHIES

Myotonic dystrophy (DM) is a chronic and slowly progressive, autosomal-dominant, multisystem disease characterized by a wide spectrum of clinical findings and by marked intrafamilial and interfamilial clinical variability. There are two genetically distinct form of DM, myotonic dystrophy type 1 (DM1) and type 2 (DM2) with different clinical phenotypes. The most frequent form is DM1 and on the basis of clinical severity the disorder is divided into three groups: mild, classical, and congenital. DM1 is caused by a (CTG)n expansion in the gene encoding Dystrophia-Myotonica-Protein-Kinase (DMPK), a zinc finger protein. When transcribed into CUG-containing RNA, mutant transcripts aggregate as nuclear foci that sequester RNA-binding proteins, resulting in a spliceopathy of downstream effector proteins (troponin, insulin
receptor, etc.). DM1 may be considered as a toxic RNA disease (Udd and Krahe, 2012; Kumar et al., 2013).

In DM1 symptoms suggestive of ANS involvement such as heart rhythm conduction disturbances, orthostatic hypotension, disorders of sweating, abnormal gut movements, and dysfunction of genital urinary apparatus are frequently referred (Aminoff et al., 1985). Conduction and heart rhythm disturbances are characterized by brady-arrhythmias leading to atrioventricular block, ectopic beats, atrial fibrillation, flutter, and other types of tachy-arrhythmias. We found a correlation between conduction system defects and (CTG)n expansion (Melacini et al., 1995). A systematic heart function follow up should be performed in DM1 patients periodically, even in asymptomatic patients to prevent sudden death.

Cardiovascular ANS is frequently studied by using cardiovascular autonomic reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).

In 23 DM1 patients a battery of cardiovascular reflex tests and spectral analysis of heart rate in time and frequency domain (Ewing and Clarke, 1982; van Ravenswaaij-Arts et al., 1993).

The cardiovascular autonomic function test was first investigated in DM1 demonstrating only minor signs of parasympathetic dysfunction and suggested that the symptoms referred to an autonomic dysfunction could be ascribed to target organ abnormality rather than to ANS dysfunction (Olofsson et al., 1990; den Heijer et al., 1991; Pierangeli et al., 1992).
Table 1 | Autonomic dysfunctions in various types of muscular dystrophies.

| Type of dystrophy | Severity of ANS involvement | Complication needing prevention or treatment |
|-------------------|-----------------------------|---------------------------------------------|
| Duchenne muscular dystrophy (DMD) | ++ | Tachycardia, atrial and ventricular arrhythmia, sweating, and chills |
| Becker muscular dystrophy (BMD) | + | Lower HRV in frequency in high arrhythmic BMD, increased sympathetic tone |
| DM1 | ++ | Orthostatic hypotension, heart rhythm disturbances, abnormal gut movements, brad-arrhythmia leading to heart block |
| EDMD | ++ | Heart block (defibrillator) |
| FSHD | ± | Tachycardia |
| Miyoshi myopathy | ± | Abnormal sympathetic skin response and vasoconstrictive response |
| FCMD | ++ + | Brain stem dysfunction, reduction of catecholaminergic neurons in reticular formation, and nucleus tractus solitarius |

Sympathetic nerve blocking produced clinical improvement (Tomoda et al., 1994).

**FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY**

Fukuyama-type congenital muscular dystrophy (FCMD) is an autosomal recessive disease caused by mutation in the fukutin gene. The study of brainstem tissue of 10 patients affected by FCMD showed a notable reduction of the catecholaminergic neurons in the reticular formation, vagal nuclei, and nucleus tractus solitarius of FCMD cases compared to controls. The Authors suggested that neuronal dysfunction in the cardiovascular and respiratory centers may lead to sudden death in FCMD (Itoh et al., 1996).

In conclusion, in agreement with ENMC International Workshop (van Engelen et al., 2005) our suggestion for autonomic dysfunction in muscular dystrophy is presented in Table 1. In particular, in DM1, cardiac problems can be unrecognized. Since physical activities precipitate arrhythmias, we advise periodic monitoring in DM1, dystrophinopathies, and EDMD. A program of HRV monitoring should be done before exercise and rehabilitation in patients with overt autonomic dysfunction.

**ACKNOWLEDGMENTS**

We thank AFM (Association Française contre les Myopathies) for a DM1-Brain grant support.

**REFERENCES**

Aminoff, M. J., Beckley, D. J., and McIlroy, M. B., (1985). Autonomic function in myotonic dystrophy. *Arch. Neurol.* 42, 16. doi: 10.1001/archneur.1985.04060010018007

Ammendola, E., Russo, V., Politano, L., Santangelo, L., and Calabro, R., (2006). Is heart rate variability a valid parameter to predict sudden death in patients with Becker’s muscular dystrophy? *Heart* 92, 1686–1987. doi: 10.1136/hrt.2005.082999

Della Marca, G., Fruscianti, R., Scatena, M., Dittioni, S., Testani, E., Vollono, C., et al. (2010). Heart rate variability in facioscapulohumeral muscular dystrophy. *Funct. Neurol.* 25, 211–216.

den Heijer, J. C., van Dijk, J. G., Bollen, W. L., Bos, J. E., and Wintzen, A. R. (1991). Assessment of autonomic function in myotonic dystrophy. *J. Neurol. Neurosurg. Psychiatry* 54, 531–534. doi: 10.1136/jnnp.54.6.531

De Stefano, M. E., Leone, L., Lombardi, L., and Paggi, P. (2005). Lack of dystrophin leads to the selective loss of superior cervical ganglion neurons projecting to muscular targets in genetically dystrophic mdx mice. *Neurobiol. Dis.* 20, 929–942. doi: 10.1016/j.nbd.2005.06.006

Di Leo, R., Rodolico, C., De Gregorio, C., Recupero, A., Gogliottore, S., Annesi, G., et al. (2004). Cardiovascular autonomic control in myotonic dystrophy type 1: a correlative study with clinical and genetic data. *Neuromusc. Disord.* 14, 136–141. doi: 10.1016/j.nmd.2003.11.002

Ducceschi, V., Nigro, G., Sarubbi, B., Comi, L. I., Politano, L., Petretta, V. R., et al. (1997). Autonomic nervous system imbalance and left ventricular systolic dysfunction as potential candidates for arrhythmogenesis in Becker muscular dystrophy. *Int. J. Cardiol.* 59, 275–279. doi: 10.1016/S0167-5273(97)02933-1

Ewing, D. J., and Clarke, B. E. (1982). Diagnosis and management of diabetic autonomic neuropathy. *Br. Med. J.* 285, 916–918. doi: 10.1136/bmj.285.6346.916

Fregonezi, G., Araujo, T., Dourado, M. E., Ferezinji, J., Silva, E., and Resqui, V. (2012). Heart rate variability in myotonic dystrophy type 1 patients. *Ang. Bras. Cardiol.* 98, 353–361. doi: 10.1590/S0668-782X2012005000021

Fujiita, T., Shimizu, M., Kaku, B., Kanaya, H., Horita, Y., Uno, Y., et al. (2005). Abnormal sympathetic innervation of the heart in a patient with Emery-Dreifuss muscular dystrophy. *Ann. Nucl. Med.* 19, 411–414. doi: 10.1007/BF03027407

Hardin, B. A., Lowe, M. R., Bhakta, D., and Groh, W. J. (2003). Heart rate variability declines with increasing age and CTG repeat length in patients with myotonic dystrophy type 1. *Ann. Noninvasive Electrocardiol.* 8, 227–321. doi: 10.1046/j.1542-474X.2003.08310.x

Heart rate variability. (1996a). Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Eur. Heart J.* 17, 354–381.

Heart rate variability. (1996b). Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Circulation* 93, 1043–1065.

Inoue, K., Ogata, H., Matsui, M., Hayano, J., Miyake, S., Kumashiro, M., et al. (1995). Assessment of autonomic function in myotonic dystrophy by spectral analysis of heart-rate variability. *J. Auton. Nerv. Syst.* 55, 131–134. doi: 10.1016/1016-1838(95)00040-5

Inoue, M., Mori, K., Hayabuchi, Y., Tatara, K., and Kagami, S. (2009). Autonomic function in patients with Duchenne muscular dystrophy. *Pediatr. Int.* 51, 33–40. doi: 10.1111/j.1442-200X.2008.02656.x

Itoh, M., Houdou, S., Kawahara, H., and Ohrama, E. (1996). Morphological study of the brainstem in Fukuyama type congenital muscular dystrophy. *Pediatr. Neurol.* 18, 327–331. doi: 10.1016/0887-9994(96)00230-5

Kumar, A., Agarwal, S., Agarwal, D., and Phadke, S. R. (2013). Myotonic dystrophy type 1 (DM1). A triple repeat expansion disorder. *Gene* 522, 226–302. doi: 10.1016/j.gene.2013.03.059

Lanza, G. A., Dello Russo, A., Giglio, V., De Luca, L., Messano, L., Santini, C., et al. (2001). Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: relationship to myocardial and respiratory function. *Am. Heart J.* 141, 808–812. doi: 10.1067/mhj.2001.114804

Magri, D., Piccirillo, G., Bucci, E., Pigatelli, G., Cauti, F. M., Morino, S., et al. (2012). Increased temporal dispersion of myocardial repolarization in myotonic dystrophy type 1: beyond the cardiac conduction system. *Int. J. Cardiol.* 156, 259–264. doi: 10.1016/j.ijcard.2010.10.132

Melacini, P., Villanova, C., Menegazzo, E., Novelli, G., Danieli, G., Rizzioli, G., et al. (1995). Correlation
between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. *J. Am. Coll. Cardiol.* 25, 239–245. doi: 10.1016/0735-1097(94)00351-P

Olofsson, B. O., Niiklasson, U., Forsberg, H., Bjerle, P., Andersson, S., and Henriksson, A. (1990). Assessment of autonomic nerve function in myotonic dystrophy. *J. Auton. Nerv. Syst.* 1990, 187–192. doi: 10.1016/0165-1838(90)90144-8

Pierangeli, G., Lugaresi, A., Contin, M., Martinelli, P., Montagna, P., Parchi, P., et al. (1992). Autonomic nervous system function in myotonic dystrophy. *Ital. J. Neurol. Sci.* 13, 589–592. doi: 10.1007/BF02233402

Politano, L., Palladino, A., Nigro, G., Scutifero, M., and Cozza, V. (2008). Usefulness of heart rate variability as a predictor of sudden cardiac death in muscular dystrophies. *Acta Myol.* 27, 114–122.

Rakočević-Stojanović, V., Milovanović, B., Ivić, N., Ille, T., Marjanović, I., Stević, Z., et al. (2007). Cardiac autonomic nervous system in patients with myotonic dystrophy type 1. *Acta Myol.* 26, 112–114.

Tomoda, A., Zhao, J. E., Ohtani, Y., Miike, T., Uchino, M., and Higuchi, I. (1994). Two patients with distal muscular dystrophy and autonomic nerve dysfunction. *Brain Dev.* 16, 65–70. doi: 10.1016/0387-7604(94)90116-3

Udd, B., and Krahe, R. (2012). The myotonic dystrophies: molecular, clinical, and therapeutic challenges. *Lancet Neurol.* 11, 891–905. doi: 10.1016/S1474-4422(12)70204-1

van Engelen, B. G. M., Eymard, B., and Wilcox, D. (2005). 123rd ENMC International Workshop: management and therapy in myotonic dystrophy. *Neuromuscul. Disord.* 15, 389–394. doi: 10.1016/j.nmd.2005.02.001

van Ravenswaaij-Arts, C. M., Kollée, L. A., Hopman, J. C., Stoelinga, G. B., and van Geijn, H. P. (1993). Heart rate variability, *Ann. Intern. Med.* 118, 436–447. doi: 10.7326/0003-4819-118-6-199303150-00008

Vita, G., Di Leo, R., De Gregorio, C., Papalia, A., Rodolico, C., Coglitore, S., et al. (2001). Cardiovascular autonomic control in Becker muscular dystrophy. *J. Neurol. Sci.* 186, 45–49. doi: 10.1016/S0022-510X(01)00500-7

Yotsukura, M., Fujii, K., Katayama, A., Tomono, Y., Ando, H., Sakata, K., et al. (1998). Nine-year follow-up study of heart rate variability in patients with Duchenne-type progressive muscular dystrophy. *Am. Heart J.* 136, 289–296. doi: 10.1016/hj.1998.v136.89737

Yotsukura, M., Sasaki, K., Kachi, E., Sasaki, A., Ishihara, T., and Ishikawa, K. (1995). Circadian rhythm and variability of heart rate in Duchenne-type progressive muscular dystrophy. *Am. J. Cardiol.* 76, 947–951. doi: 10.1016/S0002-9149(99)80267-7

Received: 28 August 2013; accepted: 01 September 2013; published online: 20 September 2013.

Citation: Angelini C, Di Leo R and Cudia P (2013) Autonomic regulation in muscular dystrophy. *Front. Physiol.* 4:257. doi: 10.3389/fphys.2013.00257

This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology.

Copyright © 2013 Angelini, Di Leo and Cudia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.